A prospective randomised controlled trial of tamoxifen and cyproterone acetate in pancreatic carcinoma.

In a prospective controlled clinical trial, 108 patients with pancreatic adenocarcinoma were randomly allocated to receive tamoxifen 20 mg b.d., cyproteron acetate 100 mg t.d.s. or no active treatment. The median survival of those receiving tamoxifen was longer than either of the other two groups (5...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Keating, J. J., Johnson, P. J., Cochrane, A. M., Gazzard, B. G., Krasner, N., Smith, P. M., Trewby, P. N., Wheeler, P., Wilkinson, S. P., Williams, R.
Médium: Artigo
Jazyk:Inglês
Vydáno: Nature Publishing Group 1989
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2247314/
https://ncbi.nlm.nih.gov/pubmed/2529892
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky